From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis

Zhou, Wendy; Frye, Joseph; Soroudi, Camille; Triadafilopoulos, George; Berry, Rani

doi:10.1007/s10620-021-07100-4

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic inflammation is characterized by basal lymphocyte infiltration, cryptic architecture distortion, and Paneth cell metaplasia (15). In contrast, inflammatory bowel disease usually manifests as granulomas or chronic structural c h a n g e s s u c h a s s h o r t e n i n g o f c r y p t s a n d b a s a l lymphoplasmacytosis (16). According to the American Society of Clinical Oncology Clinical Practice Guidelines, corticosteroids are currently the most frequently used first-line treatment for grade 2 or higher adverse events.…”

Section: Discussionmentioning

confidence: 99%

Fecal Microbiota Transplantation Effectively Cures a Patient With Severe Bleeding Immune Checkpoint Inhibitor-Associated Colitis and a Short Review

Chen

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have opened up a new way for tumor therapy but simultaneously led to the occurrence of immune-related adverse events. We report a case of successful treatment of PD-1 inhibitor-associated colitis with fecal microbiota transplantation (FMT). The patient was a palatal malignant melanoma who developed diarrhea and hematochezia accompanied by fever, gastrointestinal bleeding, and infection after the third treatment with PD-1 (Toripalimab). The patient received general treatment unsuccessful, corticosteroid therapy after initial success but rapid loss of response, and finally successful treatment after fecal microbiota transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%